A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials

Mark Von Tress,1 James S Marotta,2 Stephen S Lane,3 Ramesh Sarangapani1 1Modeling and Simulation, 2IOL Projects, 3Global Clinical Strategy, Alcon Laboratories, Fort Worth, TX, USA Purpose: The purpose of this study is to estimate and compare neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Von Tress M, Marotta JS, Lane SS, Sarangapani R
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
PCO
IOL
Acceso en línea:https://doaj.org/article/74c85cde238b480facec7308f5ccd441
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:74c85cde238b480facec7308f5ccd441
record_format dspace
spelling oai:doaj.org-article:74c85cde238b480facec7308f5ccd4412021-12-02T01:29:26ZA meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials1177-5483https://doaj.org/article/74c85cde238b480facec7308f5ccd4412018-06-01T00:00:00Zhttps://www.dovepress.com/a-meta-analysis-of-ndyag-capsulotomy-rates-for-two-hydrophobic-intraoc-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Mark Von Tress,1 James S Marotta,2 Stephen S Lane,3 Ramesh Sarangapani1 1Modeling and Simulation, 2IOL Projects, 3Global Clinical Strategy, Alcon Laboratories, Fort Worth, TX, USA Purpose: The purpose of this study is to estimate and compare neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomy rates for AcrySof® and Clareon® intraocular lens (IOL) materials using historical data from the medical literature and Alcon-sponsored clinical studies. Methods: Clinical trials that involved the implantation of AcrySof or Clareon monofocal IOLs in subjects with cataract or presbyopia were extracted from the literature and a company repository of clinical studies. The study duration, number of eyes, and cumulative percent of Nd:YAGs for posterior capsule opacification were extracted. Bayesian random effects meta-analyses were conducted to estimate and compare outcomes for the 2 different IOL materials. Results: A Bayesian random effects, meta-analysis was performed that combined a literature review of published AcrySof Nd:YAG posterior capsulotomy rates and Nd:YAG rates observed in Alcon-sponsored clinical studies of AcrySof and Clareon. Sixteen Alcon studies contained Nd:YAG data suitable for meta-analysis. Three of these Alcon studies contained results for the Clareon material (2 one-year studies, and 1 three-year study). The literature review included 50 papers from 1998 to 2015. In combination, 30,891 eyes were available for analysis and 2040 Nd:YAG procedures were reported in studies with a follow-up duration ranging in length from 4 months to 10 years. The overall probability of performing a Nd:YAG capsulotomy within a year of implant for AcrySof was 1.44% (1.11% to 1.83%) and 0.62% (0.21% to 1.38%) for Clareon. There was small improvement in the probability of Nd:YAG within a year of implant for Clareon lenses of about 0.82% with a 95% credible interval of (0.07% to 1.36%) at 1 year. Results were similar for incidence rates per 100 surgeries in a year: 0.62 (0.21 to 1.40) for Clareon, 1.46 (1.12 to 1.87) for AcrySof, and the difference was 0.84 (0.07 to 1.39) favoring Clareon. At 3 years, the overall probability of performing a Nd:YAG capsulotomy for AcrySof was 4.19% (3.24% to 5.30%) compared with only 1.82% (0.63% to 4.02%) for Clareon. Conclusion: A meta-analysis of Clareon multi-piece and single-piece clinical data predicts that the cumulative Clareon Nd:YAG probability will be ≤ AcrySof by 2.37% (0.18% to 3.91%) at 3 years. The results indicate that Clareon is likely to perform as well as, and possibly better than, AcrySof in terms of Nd:YAG capsulotomy rates. Keywords: Nd:YAG, PCO, IOL, AcrySof, Clareon, capsulotomyVon Tress MMarotta JSLane SSSarangapani RDove Medical PressarticleNd:YAGPCOIOLAcrySofClareonCapsulotomyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1125-1136 (2018)
institution DOAJ
collection DOAJ
language EN
topic Nd:YAG
PCO
IOL
AcrySof
Clareon
Capsulotomy
Ophthalmology
RE1-994
spellingShingle Nd:YAG
PCO
IOL
AcrySof
Clareon
Capsulotomy
Ophthalmology
RE1-994
Von Tress M
Marotta JS
Lane SS
Sarangapani R
A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
description Mark Von Tress,1 James S Marotta,2 Stephen S Lane,3 Ramesh Sarangapani1 1Modeling and Simulation, 2IOL Projects, 3Global Clinical Strategy, Alcon Laboratories, Fort Worth, TX, USA Purpose: The purpose of this study is to estimate and compare neodymium-doped yttrium aluminum garnet (Nd:YAG) capsulotomy rates for AcrySof® and Clareon® intraocular lens (IOL) materials using historical data from the medical literature and Alcon-sponsored clinical studies. Methods: Clinical trials that involved the implantation of AcrySof or Clareon monofocal IOLs in subjects with cataract or presbyopia were extracted from the literature and a company repository of clinical studies. The study duration, number of eyes, and cumulative percent of Nd:YAGs for posterior capsule opacification were extracted. Bayesian random effects meta-analyses were conducted to estimate and compare outcomes for the 2 different IOL materials. Results: A Bayesian random effects, meta-analysis was performed that combined a literature review of published AcrySof Nd:YAG posterior capsulotomy rates and Nd:YAG rates observed in Alcon-sponsored clinical studies of AcrySof and Clareon. Sixteen Alcon studies contained Nd:YAG data suitable for meta-analysis. Three of these Alcon studies contained results for the Clareon material (2 one-year studies, and 1 three-year study). The literature review included 50 papers from 1998 to 2015. In combination, 30,891 eyes were available for analysis and 2040 Nd:YAG procedures were reported in studies with a follow-up duration ranging in length from 4 months to 10 years. The overall probability of performing a Nd:YAG capsulotomy within a year of implant for AcrySof was 1.44% (1.11% to 1.83%) and 0.62% (0.21% to 1.38%) for Clareon. There was small improvement in the probability of Nd:YAG within a year of implant for Clareon lenses of about 0.82% with a 95% credible interval of (0.07% to 1.36%) at 1 year. Results were similar for incidence rates per 100 surgeries in a year: 0.62 (0.21 to 1.40) for Clareon, 1.46 (1.12 to 1.87) for AcrySof, and the difference was 0.84 (0.07 to 1.39) favoring Clareon. At 3 years, the overall probability of performing a Nd:YAG capsulotomy for AcrySof was 4.19% (3.24% to 5.30%) compared with only 1.82% (0.63% to 4.02%) for Clareon. Conclusion: A meta-analysis of Clareon multi-piece and single-piece clinical data predicts that the cumulative Clareon Nd:YAG probability will be ≤ AcrySof by 2.37% (0.18% to 3.91%) at 3 years. The results indicate that Clareon is likely to perform as well as, and possibly better than, AcrySof in terms of Nd:YAG capsulotomy rates. Keywords: Nd:YAG, PCO, IOL, AcrySof, Clareon, capsulotomy
format article
author Von Tress M
Marotta JS
Lane SS
Sarangapani R
author_facet Von Tress M
Marotta JS
Lane SS
Sarangapani R
author_sort Von Tress M
title A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
title_short A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
title_full A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
title_fullStr A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
title_full_unstemmed A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials
title_sort meta-analysis of nd:yag capsulotomy rates for two hydrophobic intraocular lens materials
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/74c85cde238b480facec7308f5ccd441
work_keys_str_mv AT vontressm ametaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT marottajs ametaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT laness ametaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT sarangapanir ametaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT vontressm metaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT marottajs metaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT laness metaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
AT sarangapanir metaanalysisofndyagcapsulotomyratesfortwohydrophobicintraocularlensmaterials
_version_ 1718403023125872640